HOME >> BIOLOGY >> NEWS
Chromosomal tests can determine brain tumor therapy, outcomes, Jefferson oncologists find

Philadelphia- A trial involving two types of rare, malignant but treatable brain tumors shows that missing portions of two chromosomes can predict which patients will likely do better with therapy. The results, says senior author Walter J. Curran Jr., M.D., professor and chair of radiation oncology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, represents a paradigm shift in treating such tumors, known as gliomas.

Reporting last week in the Journal of Clinical Oncology, Dr. Curran and a team of American and Canadian researchers, in conjunction with the Philadelphia-based Radiation Therapy Oncology Group (RTOG), a federally-supported clinical trials organization, found that among 289 patients with either anaplastic oligodendroglioma or anaplastic oligoastrocytoma receiving either a combination of three chemotherapy drugs with radiation or radiation alone, those whose tumors had deletions in chromosome locations 1p and 19q tended to live nearly two and a half times longer than those patients without the missing chromosome portions. The "median survival time" of patients with the deletions was greater than seven years, meaning that one-half lived at least that long. For those with tumors lacking such deletions, one-half lived at least 2.8 years.

"Leukemias used to be the only cancers where chromosomal deletions were part of the treatment decision-making process," says Dr. Curran, who is also clinical director of the Kimmel Cancer Center at Jefferson. "Now, testing for such deletions in tumors should become mandatory for at least these types of gliomas."

In the study, 147 patients received the chemotherapy and radiation, while 142 were given only radiation. These rare, malignant tumors can be effectively treated, though seldom "cured" with surgery and radiation. One controversy, explains Dr. Curran, was whether or not adding chemotherapy early in the treatment will help individuals live longer.
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
30-Jun-2006


Page: 1 2 3

Related biology news :

1. Chromosomal microarray analysis proves accurate
2. Chromosomal abnormalities in sperm higher after vasectomy reversal
3. Nearly 90 percent of babies receive recommended newborn screening tests
4. Study to probe how healthy younger adults make use of genetic tests
5. Laser goes tubing for faster body-fluid tests
6. Blood tests may be possible for mental health conditions
7. Embryo tests give parents the choice
8. Chemical tests of cell growth enter third dimension
9. Study shows prenatal diagnostic tests have low risk of miscarriage
10. Apes -- not monkeys -- ace IQ tests
11. Stress imaging tests predict prognosis of heart disease in obese persons

Post Your Comments:
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2
(Date:11/26/2014)... 2014 CURE™ magazine will ... December 5, 2014, in San Francisco prior to the ... event will honor clinicians, caregivers, and advocates who have ... (MPNs). , Special guest speaker Charles Esten, from ... journey at the reception. Over a decade ago, ...
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le lancement de ... Hi Europe 2014 (du 2 au 4 décembre à ... la plus biodisponible actuellement sur le marché, elle ... approuvés par les règlements européens. La ... racine de curcuma ( Curcuma longa ) qui ...
(Date:11/26/2014)... 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il ... occasione di Hi Europe 2014 (dal 2 al 4 ... tratta della curcumina con la maggiore biodisponibilità di sempre, ... ingredienti approvati dalle norme europee. La curcumina ... curcumina ( Curcuma longa ) che è stata associata ...
(Date:11/24/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted an additional abbreviated ... Drug Administration (FDA), which brings the Company,s total number ... submissions now pending at the FDA. ... Company, commented, "Our team here at IGI has continued ...
Breaking Biology Technology:CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2
Cached News: